Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia - 31/08/11
Abstract |
Objectives |
To evaluate the effects of finasteride, a specific type II 5-alpha-reductase inhibitor, on symptoms of benign prostatic hyperplasia, prostate volume, and urinary flow during a 7 to 8-year period.
Methods |
A total of 190 men with symptomatic benign prostatic hyperplasia and enlarged prostates entered one of two Phase II double-blind 3 to 6-month studies. Of these, 156 patients continued taking open-label finasteride, and more than 70 patients completed 7 to 8 years of treatment. The symptoms were scored using a patient self-administered modified Boyarsky symptom questionnaire. Prostate volume was measured by magnetic resonance imaging or ultrasonography, and the maximal urinary flow rate was assessed noninvasively.
Results |
Treatment with finasteride for 7 to 8 years led to sustained improvement in symptoms, reduction in prostate volume (28% from baseline), and increased urinary flow (median 2.5 mL/s from baseline). Decreases in dihydrotestosterone (86%) and prostate-specific antigen (54%) levels were also maintained. Long-term finasteride treatment was safe and generally well tolerated.
Conclusions |
Long-term treatment with finasteride was well tolerated and resulted in durable symptom relief and improvement in prostate volume and urinary flow.
Le texte complet de cet article est disponible en PDF.Plan
 | This study was funded by Merck & Co., Inc. D. Vaughan, J. Imperato-McGinley, J. McConnell, A. M. Matsumoto, B. Bracken, J. Roy, and M. Sullivan were study investigators funded by the sponsors. J. Imperato-McGinley, J. McConnell, A. M. Matsumoto, and J. Roy have been paid consultants to the sponsor. A. M. Matsumoto has also been a paid consultant to a competitor of the sponsor, GlaxoSmithKline. J. Roy holds stock in the sponsor. F. Pappas, T. Cook, C. Daurio, A. Meehan, E. Stoner, and J. Waldstreicher are employees of, and hold stock in, the sponsor. |
Vol 60 - N° 6
P. 1040-1044 - décembre 2002 Retour au numéro
Article précédent
- Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence
- Matthew B Gretzer, Jonathan I Epstein, Charles R Pound, Patrick C Walsh, Alan W Partin
- Sequential transurethral resection of the prostate and laparoscopic bladder diverticulectomy: comparison with open surgery
- F Porpiglia, R Tarabuzzi, M Cossu, F Vacca, P Destefanis, C Fiori, R.M Scarpa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?